News
All are invited to attend the NCI Technology Transfer Center’s upcoming technology opportunity webinar entitled, “Proteolysis Targeting Chimeras (PROTACs) Targeting PIM Kinase for the Treatment of Cancer,” on April 24, from 11:00 a.m. to 12:00 p.m. The inventor, S enior Investigator, Dr. John
Register to attend a free webinar to assess co-developing an NCI technology. Attendees will learn about new antibodies developed at the National Cancer Institute in the laboratory of David Fitzgerald, Ph.D. Dr. Fitzgerald and his team established that using one of the antibodies, 40H3, as an
Inventors at the National Human Genome Research Institute (NHGRI) discovered that N-acetylmannosamine (ManNAc) can be used for therapeutic purposes. ManNAc therapy given orally shows long-term safety and biochemical efficacy. ManNAc is a small uncharged physiological molecule that crosses membranes
NIH has 1,200 scientists in the Intramural Research Program who research and develop new drugs, vaccines, methods, and other products to better public health. These scientists become inventors when their research results in a licensable material or product. The NIH Record sat down with Dr. Niraj